322 related articles for article (PubMed ID: 30181086)
1. What a neurologist should know about PET and SPECT functional imaging for parkinsonism: A practical perspective.
Thobois S; Prange S; Scheiber C; Broussolle E
Parkinsonism Relat Disord; 2019 Feb; 59():93-100. PubMed ID: 30181086
[TBL] [Abstract][Full Text] [Related]
2. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.
Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J
J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112
[TBL] [Abstract][Full Text] [Related]
3. Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease.
Thobois S; Guillouet S; Broussolle E
Neurophysiol Clin; 2001 Oct; 31(5):321-40. PubMed ID: 11817273
[TBL] [Abstract][Full Text] [Related]
4. The utility of the combination of a SPECT study with [123I]-FP-CIT of dopamine transporters and [123I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes.
Uyama N; Otsuka H; Shinya T; Otomi Y; Harada M; Sako W; Izumi Y; Kaji R; Watanabe Y; Takashi S; Kunikane Y
Nucl Med Commun; 2017 Jun; 38(6):487-492. PubMed ID: 28410288
[TBL] [Abstract][Full Text] [Related]
5. 123I-ioflupane brain SPECT and 123I-MIBG cardiac planar scintigraphy combined use in uncertain parkinsonian disorders.
Nuvoli S; Spanu A; Piras MR; Nieddu A; Mulas A; Rocchitta G; Galleri G; Serra PA; Madeddu G
Medicine (Baltimore); 2017 May; 96(21):e6967. PubMed ID: 28538394
[TBL] [Abstract][Full Text] [Related]
6. [Not Available].
Prange S; Hermier M; Danaila T; Laurencin C; Thobois S
Presse Med; 2017 Mar; 46(2 Pt 1):202-209. PubMed ID: 28040345
[TBL] [Abstract][Full Text] [Related]
7. Neuroimaging in Parkinsonian Disorders.
Tripathi M; Kumar A; Bal C
Neurol India; 2018; 66(Supplement):S68-S78. PubMed ID: 29503329
[TBL] [Abstract][Full Text] [Related]
8. Distinctive regional asymmetry in dopaminergic and serotoninergic dysfunction in degenerative Parkinsonisms.
Takahashi R; Ishii K; Sousa K; Marumoto K; Kashibayashi T; Fujita J; Yokoyama K
J Neurol Sci; 2021 Apr; 423():117363. PubMed ID: 33640580
[TBL] [Abstract][Full Text] [Related]
9. [Functional neuroimaging in the diagnosis of patients with Parkinsonism: Update and recommendations for clinical use].
Arbizu J; Luquin MR; Abella J; de la Fuente-Fernández R; Fernandez-Torrón R; García-Solís D; Garrastachu P; Jiménez-Hoyuela JM; Llaneza M; Lomeña F; Lorenzo-Bosquet C; Martí MJ; Martinez-Castrillo JC; Mir P; Mitjavila M; Ruiz-Martínez J; Vela L
Rev Esp Med Nucl Imagen Mol; 2014; 33(4):215-26. PubMed ID: 24731551
[TBL] [Abstract][Full Text] [Related]
10. The utility of FDG-PET in the differential diagnosis of Parkinsonism.
Brajkovic L; Kostic V; Sobic-Saranovic D; Stefanova E; Jecmenica-Lukic M; Jesic A; Stojiljkovic M; Odalovic S; Gallivanone F; Castiglioni I; Radovic B; Trajkovic G; Artiko V
Neurol Res; 2017 Aug; 39(8):675-684. PubMed ID: 28378615
[TBL] [Abstract][Full Text] [Related]
11. [Differential diagnostics of Parkinson's disease with nuclear medicine procedures].
Meyer PT; Amtage F; Hellwig S
Nervenarzt; 2014 Jun; 85(6):680-9. PubMed ID: 24821290
[TBL] [Abstract][Full Text] [Related]
12. Imaging in Parkinson's disease.
Pagano G; Niccolini F; Politis M
Clin Med (Lond); 2016 Aug; 16(4):371-5. PubMed ID: 27481384
[TBL] [Abstract][Full Text] [Related]
13. (123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography and (123) I-metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with lewy bodies from other dementias: A comparative study.
Tiraboschi P; Corso A; Guerra UP; Nobili F; Piccardo A; Calcagni ML; Volterrani D; Cecchin D; Tettamanti M; Antelmi L; Vidale S; Sacco L; Merello M; Stefanini S; Micheli A; Vai P; Capitanio S; Gabanelli SV; Riva R; Pinto P; Biffi AM; Muscio C;
Ann Neurol; 2016 Sep; 80(3):368-78. PubMed ID: 27398636
[TBL] [Abstract][Full Text] [Related]
14. 123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders.
Rascol O; Schelosky L
Mov Disord; 2009; 24 Suppl 2():S732-41. PubMed ID: 19877202
[TBL] [Abstract][Full Text] [Related]
15.
Nuvoli S; Palumbo B; Malaspina S; Madeddu G; Spanu A
Hell J Nucl Med; 2018; 21(1):60-68. PubMed ID: 29550847
[TBL] [Abstract][Full Text] [Related]
16. [Cardiac sympathetic innervation imaging with myocardial MIBG scintigraphy].
Genovese EA; Mallardo V; Cipullo S; Restuccia A; Galea D; D'Agosto G; Di Lanno I; Cappabianca S
Recenti Prog Med; 2013; 104(7-8):356-60. PubMed ID: 24042407
[TBL] [Abstract][Full Text] [Related]
17. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.
Jeon BS; Jeong JM; Park SS; Kim JM; Chang YS; Song HC; Kim KM; Yoon KY; Lee MC; Lee SB
Ann Neurol; 1998 Jun; 43(6):792-800. PubMed ID: 9629849
[TBL] [Abstract][Full Text] [Related]
18. Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis.
Van Laere K; Casteels C; De Ceuninck L; Vanbilloen B; Maes A; Mortelmans L; Vandenberghe W; Verbruggen A; Dom R
J Nucl Med; 2006 Mar; 47(3):384-92. PubMed ID: 16513606
[TBL] [Abstract][Full Text] [Related]
19. How useful is [123I]beta-CIT SPECT in clinical practice?
Eerola J; Tienari PJ; Kaakkola S; Nikkinen P; Launes J
J Neurol Neurosurg Psychiatry; 2005 Sep; 76(9):1211-6. PubMed ID: 16107353
[TBL] [Abstract][Full Text] [Related]
20. Correlations between cerebrospinal fluid homovanillic acid and dopamine transporter SPECT in degenerative parkinsonian syndromes.
Goto R; Kurihara M; Kameyama M; Komatsu H; Higashino M; Hatano K; Ihara R; Higashihara M; Nishina Y; Matsubara T; Kanemaru K; Saito Y; Murayama S; Iwata A
J Neural Transm (Vienna); 2023 Apr; 130(4):513-520. PubMed ID: 36871130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
